Adamis wins U.S. approval to sell EpiPen rival, shares soar

(Reuters) - Adamis Pharmaceuticals Corp said on Thursday it received U.S. approval for its emergency epinephrine syringes to treat severe allergic reactions that would compete with Mylan NV's widely used EpiPen, sending its shares up more than 50 percent.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news